UroGen Pharma URGN Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's operating lease liabilities (total)?
- UroGen Pharma (URGN) reported operating lease liabilities (total) of $3.07M in Q1 2026.
- How has UroGen Pharma's operating lease liabilities (total) changed year-over-year?
- UroGen Pharma's operating lease liabilities (total) increased by 382.6% year-over-year, from $637K to $3.07M.
- What is the long-term trend for UroGen Pharma's operating lease liabilities (total)?
- Over 5 years (2020 to 2025), UroGen Pharma's operating lease liabilities (total) has grown at a 3.0% compound annual growth rate (CAGR), from $2.7M to $3.13M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.